Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (171-180 of 410) with videos related to

Pageof 41
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.
Journal of Neurosurgery. Pediatrics|July 26, 2014
Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imagingAlbert H Kim, Elizabeth A Thompson, Lance S Governale, et al.
European Urology|December 29, 2018
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized TrialDaniel J Khalaf, Katherine Sunderland, Bernhard J Eigl, et al.
Clinical Genitourinary Cancer|August 29, 2017
Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus PrednisoneCharles J Ryan, Thian Kheoh, Jinhui Li, et al.
Lab on a Chip|April 16, 2015
Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell trapsXi Qin, Sunyoung Park, Simon P Duffy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2007
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancerK N Chi, S L Ellard, S J Hotte, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 31, 2018
A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetateDaniel Joseph Khalaf, Claudia M Avilés, Arun A Azad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM TrialJimmy L Zhao, Karim Fizazi, Fred Saad, et al.
Endocrine|October 27, 2009
Coronary angiographic studies of impaired glucose regulation and coronary artery disease in Chinese nondiabetic subjectsQun Yan, Wei Q Gu, Jie Hong, et al.
Pediatric Neurology|August 1, 2006
Transverse myelitis after therapy for primitive neuroectodermal tumorsNicole J Ullrich, Karen Marcus, Scott L Pomeroy, et al.
Pageof 41

Showing results (171-180 of 410) with videos related to

Sort By:
Pageof 41
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.
Journal of Neurosurgery. Pediatrics|July 26, 2014
Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imagingAlbert H Kim, Elizabeth A Thompson, Lance S Governale, et al.
European Urology|December 29, 2018
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized TrialDaniel J Khalaf, Katherine Sunderland, Bernhard J Eigl, et al.
Clinical Genitourinary Cancer|August 29, 2017
Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus PrednisoneCharles J Ryan, Thian Kheoh, Jinhui Li, et al.
Lab on a Chip|April 16, 2015
Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell trapsXi Qin, Sunyoung Park, Simon P Duffy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2007
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancerK N Chi, S L Ellard, S J Hotte, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 31, 2018
A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetateDaniel Joseph Khalaf, Claudia M Avilés, Arun A Azad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM TrialJimmy L Zhao, Karim Fizazi, Fred Saad, et al.
Endocrine|October 27, 2009
Coronary angiographic studies of impaired glucose regulation and coronary artery disease in Chinese nondiabetic subjectsQun Yan, Wei Q Gu, Jie Hong, et al.
Pediatric Neurology|August 1, 2006
Transverse myelitis after therapy for primitive neuroectodermal tumorsNicole J Ullrich, Karen Marcus, Scott L Pomeroy, et al.
Pageof 41